NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB
Post# of 70
(Total Views: 41)
Posted On: 10/10/2025 3:53:43 AM
NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Files Provisional Patent to Strengthen Protection of AVERSA(TM) Abuse-Deterrent Technology
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the filing of a provisional patent application with the U.S. Patent and Trademark Office to expand protection for its AVERSA(TM) abuse-deterrent transdermal technology. The filing covers improved aversive formulations and coating application methods designed to enhance abuse deterrence and increase resistance to tampering. If converted to a non-provisional patent and granted, the new patent could extend AVERSA’s protection by up to 20 years from the filing date. AVERSA(TM) technology, already patented in 46 countries, incorporates aversive agents into transdermal patches to prevent misuse of drugs with abuse potential while maintaining accessibility for patients who require them..
The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the filing of a provisional patent application with the U.S. Patent and Trademark Office to expand protection for its AVERSA(TM) abuse-deterrent transdermal technology. The filing covers improved aversive formulations and coating application methods designed to enhance abuse deterrence and increase resistance to tampering. If converted to a non-provisional patent and granted, the new patent could extend AVERSA’s protection by up to 20 years from the filing date. AVERSA(TM) technology, already patented in 46 countries, incorporates aversive agents into transdermal patches to prevent misuse of drugs with abuse potential while maintaining accessibility for patients who require them..
The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)